|
Publications |
[35] Schreier, V. N., Mező, G., Orbán, E., Dürr, C., Marquardt, A., Manea, M. *(2013) “Synthesis, enzymatic stability and in vitro cytostatic effect of Daunorubicin-GnRH-III derivative dimers” Bioorg. Med. Chem. Lett. DOI: 10.1016/j.bmcl.2013.01.114. (*corresponding author)
[34] Limonta, P., Manea, M. (2013) “Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: current options and emerging strategies” Cancer Treat. Rev. DOI: 10.1016/j.ctrv.2012.12.003.
[33] Paraschiv, G., Vincke, C., Czaplewska, P., Manea, M., Muyldermans, S., Przybylski, M. (2013) “Epitope structure and binding affinity of single chain llama anti-β-amyloid antibodies revealed by proteolytic excision affinity-mass spectrometry” J. Mol. Recognit. 26(1):1-9.
[32] Flangea, C., Schiopu, C., Capitan, F., Mosoarca, C., Manea, M., Sisu, E., Zamfir, A.D. (2013) “Fully automated chip-based nanoelectrospray combined with electron transfer dissociation for high throughput top-down proteomics” Cent. Eur. J. Chem. 11(1):25-34.
[31] Manea, M., Mező, G. (2013) “lGnRH-III - a Promising Candidate for Anticancer Drug Development” Protein Pept Lett. 20(4):439-449.
[30] Maftei, M. #, Thurm, F. #, Leirer, V. M., von Arnim, C. A. F., Elbert, T., Przybylski, M., Kolassa, I.-T.*, Manea, M.* (2012) “Antigen-bound and free ß-amyloid autoantibodies in serum of healthy adults” PLoS ONE. 7(9):e44516. (*corresponding author)
[29] Hegedüs, R., Manea, M., Orbán, E., Szabó, I., Kiss, É., Sipos, É., Halmos, G., Mező, G. (2012) “Enhanced cellular uptake and in vitro antitumor activity of short-chain fatty acid acylated daunorubicin-GnRH-III bioconjugates” Eur. J. Med. Chem. 56C, 155-165.
[28] Maftei, M., Tian, X., Manea, M.*, Exner, T., Schwanzar, D., von Arnim, C., Przybylski, M. (2012) "Interaction structure of the complex between neuroprotective factor humanin and Alzheimer’s β-amyloid peptide revealed by affinity-mass spectrometry and molecular modelling" J. Peptide Sci. 18(6):373-382.
[27] Leurs, U.#, Lajkó, E.#, Mező, G., Orbán, E., Öhlschläger, P., Marquardt, A., Kőhidai, L.*, Manea, M.* (2012) "GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate" Eur. J. Med. Chem. 52:173-183. (*corresponding author)
[26] Leurs, U., Mező, G., Orbán, E., Öhlschläger, P., Marquardt, A., Manea, M.* (2012) "Design, synthesis, in vitro stability and cytostatic effect of multifunctional anticancer drug-bioconjugates containing GnRH-III as a targeting moiety" Biopolymers Pept. Sci. 98:1-10. (*corresponding author)
[25] Manea, M., Tóvári, J., Tejeda, M., Schulcz, Á., Kapuvári, B., Vincze, B., Mező, G. (2012) "In vivo antitumor effect of daunorubicin – GnRH-III derivative conjugates on colon carcinoma bearing mice" Anti-Cancer Drugs 23(1):90-97.
[24] Orbán, E., Manea, M., Marquadt, A., Bánóczi, Z., Csík, G., Fellinger, E., Bősze, Sz., Hudecz, F. (2011) "A new daunomycin-peptide conjugate: Synthesis, chraracterization and the effect on protein expression profile of HL-60 cells in vitro" Bioconjug. Chem. 22(10):2154-2165.
[23] Schlage, P., Mező, G.*, Orbán, E., Bősze, Sz., Manea, M.* (2011) "Anthracycline-GnRH derivative bioconjugates with different linkages: synthesis, in vitro drug release and cytostatic effect" J. Control. Release 156(2):170-178. (*corresponding author)
[22] Manea, M.*, Leurs, U., Orbán, E., Baranyai, Zs., Öhlschläger, P., Marquardt, A., Schulcz Á., Tejeda, M., Kapuvári, B., Tóvári, J., Mező, G. (2011) "Enhanced enzymatic stability and antitumor activity of daunorubicin-GnRH-III bioconjugates modified in position 4" Bioconjug. Chem. 22(7):1320-1329. (*corresponding author)
[21] Mező, G.*, Szabó, I., Kertész, I., Hegedüs, R., Orbán, O., Leurs, U., Bősze, Sz., Halmos, G., , Manea, M.* (2011) “Efficient synthesis of an (aminooxy)acetyled somatostatin derivative using (aminooxy)acetic acid as a „carbonyl capture” reagent”, J. Peptide Sci. 17(1):39-46 (*corresponding author).
[20] Orbán, E., Mező, G.*, Schlage, P., Csík, G., Kulić, Ž., Ansorge, F., Fellinger, E., Möller, H., Manea, M.* (2010) “In vitro degradation and antitumor activity of oxime bond-linked daunorubicin-GnRH-III bioconjugates and DNA-binding properties of daunorubicin-amino acid metabolites”, Amino Acids, 41(2):469-483. (*corresponding author).
[19] Mező, G., Manea, M. (2010) “Receptor mediated tumor targeting based on peptide hormones”, Expert Opinion on Drug Delivery 7(1):79-96.
[18] Mező, G., Manea, M. (2009) “Luteinizing hormone-releasing hormone antagonists”, Expert Opinion on Therapeutic Patents 19(12):1771-85.
[17] Drochioiu, G., Manea, M., Dragusanu, M., Murariu, M., Dragan, E.S., Petre, B.A., Mezo, G., Przybylski, M. (2009) “Interaction of beta-amyloid(1-40) peptide with pairs of metal ions: An electrospray ion trap mass spectrometric model study”. Biophys. Chem. 144(1-2):9-20
[16] Jung, J.E.*, Wollscheid, H.P.*, Marquardt, A., Manea, M., Scheffner, M., Przybylski, M. (2009) “Functional ubiquitin conjugates with lysine-epsilon-amino-specific linkage by thioether ligation of cysteinyl-ubiquitin peptide building blocks”. Bioconjug. Chem. 20(6):1152-1162; (*equal contribution).
[15] Szabó, I.*, Manea, M.*, Orbán, E, Csámpai, A., Bősze, S., Szabó, R., Tejeda, M., Gaál, D., Kapuvári, B., Przybylski, M., Hudecz, F., Mező, G. (2009) “Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug”, Bioconjug. Chem. 20(4):656-665 (*equal contribution).
[14] Jakab, A., Schlosser, G., Feijlbrief, M., Welling-Wester, S., Manea, M., Vila-Perello, M., Andreu, D., Hudecz, F., Mező, G. (2009) “Synthesis and antibody recognition of cyclic epitope peptides, together with their dimer and conjugated derivatives based on residues 9-22 of herpes simplex virus type 1 glycoprotein D”, Bioconjug. Chem. 20(4):683-692.
[13] Mező, G, Manea, M., Szabó, I., Vincze, B., Kovács, M. (2008) “New derivatives of GnRH as potential anticancer therapeutic agents”, Curr. Med. Chem. 15(23):2366-2379.
[12] Manea, M.*, Kalászi, A.*, Mező, G., Horváti, K., Horváth, A., Farkas, Ö., Przybylski, M., Hudecz, F. (2008) “Antibody recognition and conformational flexibility of a plaque-specific ß-amyloid epitope modulated by non-native peptide flanking regions”, J. Med. Chem. 51(5):1150-1161 (*equal contribution).
[11] Manea, M.*, Przybylski, M., Hudecz, F., Mező G. (2008) “Design, structural and immuno-analytical properties of antigenic bioconjugates comprising a ß-amyloid-plaque specific epitope”, Biopolymers Peptide Science 90(2):94-104 (*corresponding author).
[10] Drochioiu, G., Murariu, M., Petre, A.B., Manea, M., Przybylski, M. (2007) “Synthesis and characterization of a nonapeptides with specific properties for Cu binding” Revista de chimie 58(3): 311-315.
[9] Stefanescu, R., Iacob, R. E., Damoc, E. N., Marquardt, A., Amstalden, E., Manea, M., Perdivara, I., Maftei, M., Paraschiv, G., Przybylski, M. (2007) “Mass spectrometric approaches for elucidation of antigen–antibody recognition structures in molecular immunology.” Eur. J. Mass Spectrom. 13(1), 69-75.
[8] Manea, M., Mező G., Hudecz, F., Przybylski, M. (2007) “Mass spectrometric identification of trypsin cleavage pathway in lysyl-proline containing peptides”, J. Peptide Sci. 13(4), 227-236.
[7] Mező, G., Czajlik, A., Manea, M., Jakab, A., Farkas, V., Majer, Zs., Vass, E., Bodor, A., Kapuvári, B., Boldizsár, M., Vincze, B., Csuka, O., Kovács, M., Przybylski, M., Perczel, A., Hudecz, F. (2007) “Structure, Enzymatic stability and antitumor activity of sea lamprey GnRH-III and its dimer derivatives.” Peptides 28(4), 806-820.
[6] Manea M., Hudecz F., Przybylski M., Mező G. (2005) "Synthesis, solution conformation and antibody recognition of oligotuftsin based conjugates containing a ß-amyloid(4-10) plaques specific epitope", Bioconjug. Chem. 16(4), 921-928.
[5] Tian X., Cecal R., McLaurin J., Manea M., Stefanescu R., Grau S., Harnasch M., Amir S., Ehrmann M., St. George-Hyslop P., Kohlmann M., Przybylski M. (2005) "Identification and structural characterisation of carboxy-terminal polypeptides and antibody epitopes of Alzheimer's amyloid precursor protein using high resolution mass spectrometry", Eur. J. Mass Spectrom. 11(5), 547-556.
[4] Manea M., Mező G., Hudecz F., Przybylski M. (2004) "Polypeptide conjugates comprising a ß-amyloid plaque-specific epitope as new vaccine structures against Alzheimer's disease", Biopolymers, 76(6), 503-511.
[3] Mező G., Manea M., Jakab A., Kapuvári B., Bősze S., Schlosser G., Przybylski M., Hudecz F. (2004) "Synthesis and structural characterization of bioactive peptide conjugates using thioether linkage approaches", J. Peptide Sci. 10(12), 701-713.
[2] Zirah, S., Stefanescu, R., Manea, M., Tian, X., Cecal, R., Kozina, D.A., Debey, P., Rebuffat, S., Przybylski, M. (2004) “Zinc binding agonist effect on the recognition of the ß-amyloid (4-10) epitope by anti-ß-amyloid antibodies”, Biochem. Biophys. Res. Commun. 321(2), 324-328.
[1] McLaurin, J., Cecal, R. E., Kierstead, M., Tian, X., Phinney, A., Manea, M., French, M., Lambermon, M., Darabie, A., Brown, M., Janus, C., Chishti, C., Horne, P., Westaway, D., Fraser, P., Mount, H., Przybylski, M., and St George-Hyslop, P. (2002) “Therapeutically effective antibodies against amyloid-ß peptide target amyloid-ß residues 4-10 and inhibit cytotoxicity and fibrillogenesis“, Nature Medicine 8(11), 1263-1269.
|
|
